JP2007536933A5 - - Google Patents

Download PDF

Info

Publication number
JP2007536933A5
JP2007536933A5 JP2007513283A JP2007513283A JP2007536933A5 JP 2007536933 A5 JP2007536933 A5 JP 2007536933A5 JP 2007513283 A JP2007513283 A JP 2007513283A JP 2007513283 A JP2007513283 A JP 2007513283A JP 2007536933 A5 JP2007536933 A5 JP 2007536933A5
Authority
JP
Japan
Prior art keywords
seq
cell
antibody
pharmaceutical composition
immunoglobulin chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007513283A
Other languages
English (en)
Japanese (ja)
Other versions
JP5623690B2 (ja
JP2007536933A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/016357 external-priority patent/WO2005110475A2/en
Publication of JP2007536933A publication Critical patent/JP2007536933A/ja
Publication of JP2007536933A5 publication Critical patent/JP2007536933A5/ja
Application granted granted Critical
Publication of JP5623690B2 publication Critical patent/JP5623690B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2007513283A 2004-05-10 2005-05-10 抗体 Expired - Lifetime JP5623690B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56989204P 2004-05-10 2004-05-10
US60/569,892 2004-05-10
PCT/US2005/016357 WO2005110475A2 (en) 2004-05-10 2005-05-10 Antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011121078A Division JP2011200247A (ja) 2004-05-10 2011-05-30 抗体

Publications (3)

Publication Number Publication Date
JP2007536933A JP2007536933A (ja) 2007-12-20
JP2007536933A5 true JP2007536933A5 (enExample) 2008-06-26
JP5623690B2 JP5623690B2 (ja) 2014-11-12

Family

ID=35394680

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2007513283A Expired - Lifetime JP5623690B2 (ja) 2004-05-10 2005-05-10 抗体
JP2011121078A Pending JP2011200247A (ja) 2004-05-10 2011-05-30 抗体
JP2014003463A Pending JP2014094010A (ja) 2004-05-10 2014-01-10 抗体
JP2014156064A Withdrawn JP2014223084A (ja) 2004-05-10 2014-07-31 抗体

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2011121078A Pending JP2011200247A (ja) 2004-05-10 2011-05-30 抗体
JP2014003463A Pending JP2014094010A (ja) 2004-05-10 2014-01-10 抗体
JP2014156064A Withdrawn JP2014223084A (ja) 2004-05-10 2014-07-31 抗体

Country Status (27)

Country Link
US (8) US7604800B2 (enExample)
EP (3) EP2377890B1 (enExample)
JP (4) JP5623690B2 (enExample)
KR (1) KR101256400B1 (enExample)
CN (2) CN103980361B (enExample)
AR (1) AR048781A1 (enExample)
AU (1) AU2005244072C1 (enExample)
BR (1) BRPI0510567B8 (enExample)
CA (3) CA2812040C (enExample)
DK (1) DK1765396T3 (enExample)
EC (1) ECSP067056A (enExample)
EG (1) EG26781A (enExample)
ES (3) ES2598034T3 (enExample)
IL (3) IL178838A (enExample)
MX (1) MXPA06012986A (enExample)
MY (1) MY148646A (enExample)
NO (1) NO341844B1 (enExample)
NZ (3) NZ590690A (enExample)
PH (1) PH12015500247A1 (enExample)
PL (1) PL1765396T3 (enExample)
PT (1) PT1765396E (enExample)
RU (1) RU2482131C2 (enExample)
SG (2) SG187443A1 (enExample)
TW (2) TWI448474B (enExample)
UA (1) UA100356C2 (enExample)
UY (1) UY28886A1 (enExample)
WO (1) WO2005110475A2 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040116333A1 (en) 2001-08-03 2004-06-17 Rong-Hwa Lin Modulators of P-selectin glycoprotein ligand 1
US7744888B2 (en) 2001-08-03 2010-06-29 Abgenomics Cooperatief U.A. Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies
UY28886A1 (es) 2004-05-10 2005-12-30 Boehringer Ingelheim Int Anticuerpos que consisten en polipéptidos y derivados conprendiendo tres secuencias conteniendo respectivamente los siguientes números de seq. id: 1-3 y 4-6; 7-9 y 10-12 y 13-15 ó 16-18
MXPA06012987A (es) * 2004-05-11 2007-06-12 Abgenomics Corp Epitopos inductores de muerte de celulas t.
US20070160601A1 (en) * 2005-12-09 2007-07-12 Angela Widom Neutralizing antibodies against primate psgl-1 and uses therefor
CN102264765B (zh) * 2008-10-28 2016-01-20 盐野义制药株式会社 抗muc1抗体
TWI606520B (zh) * 2008-10-31 2017-11-21 半導體能源研究所股份有限公司 半導體裝置及其製造方法
GB0822011D0 (en) * 2008-12-02 2009-01-07 Queen Mary & Westfield College Treatment
PT3023438T (pt) 2009-09-03 2020-05-08 Merck Sharp & Dohme Anticorpos anti-gitr
CA2803937A1 (en) * 2010-06-30 2012-01-05 Mount Sinai Hospital Reagents and methods for diagnosing conditions associated with hydroxylated hif 1-a
ES2387156B1 (es) * 2010-12-01 2013-07-04 Universidad Autónoma de Madrid Uso de psgl-1 para el tratamiento de enfermedades inflamatorias y autoinmunes
US20130209449A9 (en) * 2011-06-13 2013-08-15 Abgenomics Cooperatief U.A. Anti-psgl-1 antibodies and uses thereof
MX2014004025A (es) 2011-10-17 2014-08-01 Univ Muenster Wilhelms Metodos de valoracion de riesgo de lmp y aparatos relacionados.
CA2881966C (en) 2012-08-24 2020-10-06 The Regents Of The University Of California Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
TWI595007B (zh) * 2012-09-10 2017-08-11 Neotope Biosciences Ltd 抗ｍｃａｍ抗體及相關使用方法
CN108135986B (zh) * 2015-08-13 2022-07-29 纽约大学 对于Tau的截短的Asp421表位特异性的基于抗体的分子和它们在诊断和治疗Tau疾病中的用途
JP7078536B2 (ja) * 2016-01-08 2022-05-31 アルトゥルバイオ， インコーポレイテッド 四価抗ｐｓｇｌ－１抗体とその使用
WO2017214941A1 (zh) * 2016-06-16 2017-12-21 毛侃琅 一种提升SelP基因表达水平的慢病毒载体及其应用
EP3474854A4 (en) 2016-06-27 2020-02-19 The Regents of The University of California CANCER TREATMENT COMBINATIONS
KR102630011B1 (ko) * 2017-01-11 2024-01-26 브리스톨-마이어스 스큅 컴퍼니 Psgl-1 길항제 및 그의 용도
EP3595720A4 (en) 2017-03-14 2021-05-26 Five Prime Therapeutics, Inc. ANTIBODIES BINDING VISTA AT ACIDIC PH VALUE
MX2020009786A (es) 2018-03-21 2020-10-12 Five Prime Therapeutics Inc Anticuerpos de union a supresor de la activacion de celulas t que contiene el dominio variable de inmunoglobulina (vista) a ph acido.
WO2020014327A2 (en) 2018-07-11 2020-01-16 Five Prime Therapeutics, Inc. Antibodies binding to vista at acidic ph
IL280199B2 (en) 2018-07-20 2025-08-01 Pf Medicament Receptor for vista
JP7716992B2 (ja) * 2019-06-04 2025-08-01 ヴェルソー セラピューティクス， インコーポレイテッド 骨髄細胞炎症性表現型を調節するための抗ｐｓｇｌ－１組成物及び方法、ならびにその使用
WO2021148003A1 (zh) * 2020-01-22 2021-07-29 上海森辉医药有限公司 艾日布林衍生物的药物偶联物、其制备方法及其在医药上的应用
CN118696059A (zh) * 2021-11-17 2024-09-24 美国全心医药生技股份有限公司 使用抗psgl-1抗体与jak抑制剂的组合治疗t细胞介导的炎症性疾病或癌症的方法
WO2025106784A1 (en) * 2023-11-17 2025-05-22 Altrubio Inc. Anti-psgl-1 antibodies and uses thereof

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5378464A (en) 1989-03-08 1995-01-03 Board Of Regents Of The University Of Oklahoma Modulation of inflammatory responses by administration of GMP-140 or antibody to GMP-140
US5464778A (en) 1989-03-08 1995-11-07 Board Of Regents Of The University Of Oklahoma Glycoprotein ligand for P-selectin and methods of use thereof
US5690933A (en) 1989-05-31 1997-11-25 Glaxo Wellcome Inc. Monoclonal antibodies for inducing tolerance
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5709859A (en) 1991-01-24 1998-01-20 Bristol-Myers Squibb Company Mixed specificity fusion proteins
US6124267A (en) 1991-02-05 2000-09-26 Southpac Trust Internationals, Inc. O-glycan inhibitors of selectin mediated inflammation derived from PSGL-1
US6309639B1 (en) 1991-02-05 2001-10-30 The Board Of Regents Of The University Of Oklahoma Method for inhibiting an inflammatory response using antibodies to P-selectin glycoprotein ligand
US5972625A (en) 1991-05-06 1999-10-26 The Regents Of The University Of California Assays for inhibitors of leukocyte adhesion
WO1993019180A1 (en) 1992-03-17 1993-09-30 Ciba-Geigy Ag Genetically engineered antibodies
US5843707A (en) 1992-10-23 1998-12-01 Genetics Institute, Inc. Nucleic acid encoding a novel P-selectin ligand protein
CA2149025A1 (en) * 1992-12-01 1994-06-09 Man Sung Co Humanized antibodies reactive with l-selectin
US6210671B1 (en) * 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
US5710123A (en) 1992-12-18 1998-01-20 Centocor, Inc. Peptide inhibitors of selectin binding
EP0689599B1 (en) 1993-01-25 1998-12-09 Dana-Farber Cancer Institute, Inc. Chimeric selectins by exchange of domains - uses thereof
CZ287295A3 (en) * 1993-05-05 1996-05-15 Cytel Corp Antibodies against p-selectin, method of detecting p-selectin, preparation processes of medicaments, pharmaceutical preparations, nucleic acids, cell lines and their use
WO1995014787A1 (en) 1993-11-22 1995-06-01 Centocor, Inc. Peptide inhibitors of selecting binding
KR100523506B1 (en) 1995-08-03 2005-10-24 Peptide and O-glycan inhibitors of selectin mediated inflammation
US6348581B1 (en) * 1996-10-31 2002-02-19 The Dow Chemical Company High affinity humanized anti-TAG-72 monoclonalantibodies
JP3248570B2 (ja) * 1997-10-09 2002-01-21 日本電気株式会社 半導体装置の製造方法
WO1999043353A2 (en) 1998-02-26 1999-09-02 Boehringer Ingelheim Pharmaceuticals, Inc. Combination anti-selectin and immunosuppressant therapy
EP1131084A4 (en) * 1998-10-30 2001-12-19 Genetics Inst INHIBITION OF DIFFERENTIATION OF CYTOTOXIC T CELLS BY P-SELECTINE LIGAND ANTAGONISTS (PSGL)
US6696620B2 (en) 2000-05-02 2004-02-24 Epicyte Pharmaceutical, Inc. Immunoglobulin binding protein arrays in eukaryotic cells
JP2003534291A (ja) * 2000-05-19 2003-11-18 ザ センター フォー ブラッド リサーチ インク Ｐ−セレクチン活性の変調による止血障害の診断及び治療方法
CN1124928C (zh) * 2000-07-11 2003-10-22 湛江包装材料企业有限公司 光降解双向拉伸聚丙烯薄膜的制造方法
EP1325123A4 (en) * 2000-09-12 2004-07-21 Inst Genetics Llc STENOSE- OR RESEARCH INHIBITION BY P-SELECTIN ANTAGONISTS
EP1406930A4 (en) 2000-12-29 2007-01-10 Savient Pharmaceuticals Inc "ISOLATED MOLECULES WITH SULFATED GROUPING CONTAINING EPITOPES, ANTIBODIES AGAINST SUCH EPITOPES AND USES THEREOF"
US20040002450A1 (en) * 2000-12-29 2004-01-01 Janette Lazarovits Y17 - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US20040001839A1 (en) * 2000-12-29 2004-01-01 Avigdor Levanon Multimers - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US6884619B2 (en) * 2001-07-17 2005-04-26 Yale University Inhibition of BEHAB cleavage and primary central nervous system (CNS) tumors
US20040116333A1 (en) * 2001-08-03 2004-06-17 Rong-Hwa Lin Modulators of P-selectin glycoprotein ligand 1
US7744888B2 (en) * 2001-08-03 2010-06-29 Abgenomics Cooperatief U.A. Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies
UY28886A1 (es) 2004-05-10 2005-12-30 Boehringer Ingelheim Int Anticuerpos que consisten en polipéptidos y derivados conprendiendo tres secuencias conteniendo respectivamente los siguientes números de seq. id: 1-3 y 4-6; 7-9 y 10-12 y 13-15 ó 16-18
MXPA06012987A (es) 2004-05-11 2007-06-12 Abgenomics Corp Epitopos inductores de muerte de celulas t.
US20130209449A9 (en) 2011-06-13 2013-08-15 Abgenomics Cooperatief U.A. Anti-psgl-1 antibodies and uses thereof

Similar Documents

Publication Publication Date Title
RU2487723C2 (ru) Химерные и гуманизированные антитела к cd44, которые опосредствуют цитотоксичность в отношении раковых клеток
RU2505603C2 (ru) Антитело против рецептора il-6
ES2917000T3 (es) Interferón-gamma mutante diana y usos del mismo
Valent et al. Immunotherapy-based targeting and elimination of leukemic stem cells in AML and CML
US9624276B2 (en) Peptidic chimeric antigen receptor T cell switches and uses thereof
JP2007500132A5 (enExample)
HRP20201770T1 (hr) Nova imunoterapija protiv raznih vrsta karcinoma, uključujući gastrointestinalni karcinom i gastrični karcinom
AU2025263899A1 (en) Fibroblast binding agents and use thereof
RU2019119442A (ru) Новый коньюгат аманитина
CA2451353A1 (en) Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer
JP2013541335A5 (enExample)
EP2860189A3 (en) Human cytomegalovirus neutralising antibodies and use thereof
MA43330B1 (fr) Lymphocytes t transfectés et récepteurs de lymphocytes t destinés à être utilisés en immunothérapie contre des cancers
MA43328A1 (fr) Lymphocytes t transfectés et récepteurs de lymphocytes t destinés à être utilisés en immunothérapie contre des cancers
JP2015508757A5 (enExample)
EP2604693A3 (en) TNFSF single chain molecules
RU2006143686A (ru) Антитела
JP2010533498A5 (enExample)
JP2010502207A5 (enExample)
JP2006523453A5 (enExample)
NZ513498A (en) Monoclonal antibodies, antigens and diagnosis and therapy of malignant diseases
JP2012143232A5 (enExample)
FI3277321T3 (fi) T-soluimmunoglobuliinia ja musiiniproteiini 3:a (tim-3) vastaan suunnattuja vasta-aineita
JP2020500510A5 (enExample)
HRP20190799T1 (hr) Imunocitokini na bazi il-15 i sushi domene il-15r alfa